In Sweden approximately 4 000 people are annually diagnosed with a hematological cancer. The most common types are lymphomas, leukemia and multiple myeloma. In large population-based studies we have been able to demonstrate that the prognosis has improved in most of these disorders, mainly due to better methods of diagnosis and treatment. However, many patients still succumb from their disease. In addition, patients who have been cured from their hematological cancer are at risk of developing complications related to treatment including secondary tumors, cardiovascular disease, impaired fertility and hormonal dysregulation.
The overriding goal of our research is to improve outcome of patients through identification of risk factors for development of disease and to reveal new biological tumor characteristics, with a special focus on synthesis and function of fatty acid products in Hodgkin and other lymphomas. The results can hopefully lead to better preventive measures, improved diagnostics, and novel principals of treatments. Our discoveries are made possible through a research team represented by several different academic fields, including experimental researchers in inflammation and tumor biology together with clinical and epidemiological competences. In addition, access to unique Swedish population registers is another critical success factor. Acute myeloid leukemia, multiple myeloma and myeloproliferative neoplasms are other important research areas.
If you would like to support this area of research you could do that by using the following accounts:
State: Magnus Björkholm
If you are outside of Sweden, please use the following information:
Bank: SEB, Stockholm, Sweden
Account No. 5201-11 370 12
Iban-number: SE16 5000 0000 0520 1113 7012
Bic-code (the bank´s electronic address): ESSESESS
Account holder: Center for Molecular Medicine Foundation
L8:05, Karolinska University Hospital
171 76 Stockholm, Sweden